darusentan (HMR-4005) / Gilead - LARVOL DELTA

EFFECTS OF ENDOTHELIN AND ANGIOTENSIN RECEPTOR BLOCKADE ON CYTOKINE SIGNALING IN RENAL MESANGIAL AND GLOMERULAR ENDOTHELIAL CELLS (ISN-WCN 2024) - "The cells were further divided into four groups depending on exposure to Losartan (LOS 10uM) or Darusentan (DAR 10uM) or a combination (DAR+LOS) or control (none). In cultured renal glomerular endothelial cells, exposure to high glucose caused decreased expression of eNOS which mediates constitutive NO production. Treatment with LOS and DAR and especially DAR increased NO production in these cells. NO has salutary benefits in slowing the progression of DN."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Nephrology • Renal Disease • CTGF • NOS3

Efficacy of pharmacological and interventional treatment for resistant hypertension-a network meta-analysis. (PubMed, Cardiovasc Res) - "Among all pharmacologic and interventional treatments, spironolactone is the most effective in reducing blood pressure in patients with resistant hypertension. More comparative trials and especially trials with long-term follow up are needed. In the meanwhile, we have to conclude that a combination of spironolactone and lifestyle modification are the most effective treatments in resistant hypertension."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. (PubMed) - J Gen Intern Med - "When compared to MRA as anchor, darusentan, CAA and RDN are not more effective in achieving a clinically significant reduction in ambulatory blood pressure in individuals with apparent treatment-resistant hypertension."

Journal • Biosimilar • Cardiovascular